Background: Whether extending the treatment length and the use of high-dose esomeprazole may optimize the efficacy of Helicobacter pylori eradication remains unknown.
Introduction
The eradication rate for Helicobacter pylori infection, a causal factor of peptic ulcer disease and gastric cancer, [1] [2] [3] is decreasing due to the rising prevalence of antibiotic resistance. [4] [5] [6] The efficacies of H. pylori eradication regimens may be optimized through the use of four-drug regimens (bismuth quadruple therapy, or concomitant therapy, or sequential therapy), extending its length to 14 days, and the use of a higher dosage of proton pump inhibitor (PPI). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] Sequential therapy given for 10 days has been extensively compared with triple therapy and concomitant therapy of various treatment lengths in randomized controlled trials (RCTs). 12, 13, 16 Meta-analysis of these trials showed that 10 day sequential therapy was more effective than 7 or 10 day triple therapy, but was not superior to 14 day triple therapy. 12, 14, 18 A recent meta-analysis of RCTs showed that the efficacy of 10 day sequential therapy was superior to 5 day concomitant therapy, similar to 7 day concomitant therapy, but was inferior to 10 day concomitant therapy. 25 Therefore, the Maastricht V Consensus and the Toronto Consensus recommended against the use of 10 day sequential therapy for the first-line treatment of H. pylori infection. 9, 10 However, sequential therapy remains one of the treatment choices in the ACG guideline. 11 Recently, we showed that 10 day bismuth quadruple therapy, but not 10 day concomitant therapy, was superior to 14 day triple therapy in Taiwan where the prevalence of clarithromycin resistance was 15%. 17 Therefore, we conducted this RCT to compare the efficacy and tolerability of optimized 14 day sequential therapy containing high-dose esomeprazole and 10 day bismuth quadruple therapy in first-line therapy. The efficacy of bismuth quadruple therapy and optimized 14 day sequential therapy in second-line rescue therapy and factors that might affect their efficacies were also assessed. Finally, we constructed the Hp-normogram 26 to estimate the efficacy of the two regimens in regions with a different prevalence of antibiotic resistance.
Patients and methods

Trial design and settings
The Institutional Review Board of each participating hospital approved this open-label, multicentre, randomized trial. Written informed consent was obtained from all patients prior to enrolment. The Clinical Trial.gov registration identifier is NCT03156855.
Participants
We recruited both symptomatic and asymptomatic adult subjects (20 years of age) in seven medical centres in Taiwan. The recruitment criteria and exclusion criteria were similar to our previous trials. 13, 16, 17 Symptomatic patients who underwent oesophagogastroduodenoscopy due to dyspepsia or other symptoms were invited to a screening programme for H. pylori. Patients with at least two positive tests among histology, rapid urease test, culture and serology were eligible for enrolment (Criterion 1). Asymptomatic subjects who underwent gastric cancer screening with a single positive 13 C-urea breath test ( 13 C-UBT) were also eligible for enrolment (Criterion 2). Patients with any one of the following criteria were excluded from the study: (i) history of prior H. pylori eradication therapy; (ii) history of gastrectomy; (iii) severe concurrent illness or non-curative malignancy; (iv) pregnant or lactating women; (v) contraindication or previous allergic reactions to the study drugs; and (vi) patients who could not give informed consent for themselves. Study research staff explained the purpose and eligibility requirements of the study to potential participants.
Randomization, blinding and intervention
Eligible patients were randomized to receive either one of the following regimens: (i) optimized sequential therapy for 14 days (ST14): esomeprazole 40 mg and amoxicillin 1 g for 7 days, followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg for another 7 days (all given twice daily), or (ii) bismuth quadruple therapy for 10 days (BQ10): esomeprazole 40 mg twice daily, bismuth tripotassium dicitrate 300 mg (KCB F.C. Tablets; Swiss Pharm, Taiwan) four times a day, tetracycline 500 mg four times a day and metronidazole 500 mg three times a day for 10 days. The block randomization sequence with a block size of 4 in a 1:1 ratio was generated by computer. The sequence was concealed in an opaque envelope and kept by an independent research assistant (Miss Huang) in the Call Centre, the National Taiwan University Hospital (NTUH), until intervention was assigned. The study nurses from each centre contacted the independent assistant to obtain the next allocation number by phone after having obtained the written informed consents from eligible subjects to ensure adequate allocation concealment. All investigators were blind to the randomization sequence. Patients who remained positive for H. pylori after first-line 14 day sequential therapy or 10 day bismuth quadruple therapy were retreated with 10 day bismuth quadruple therapy and 14 day sequential therapy, respectively. The dosage and frequency of each regimen in the second-line treatment were the same as that of the first-line treatment.
Outcome assessment
The primary endpoint of the study was the eradication rate in the first-line therapy. The secondary endpoints were the frequency of adverse effects and the compliance with the first-line therapy and the eradication rates in the second-line therapy. The eradication status was determined by 13 C-UBT at least 6 weeks after completion of treatment. All subjects were asked to discontinue histamine-2 blocker and PPI for at least 2 weeks before 13 C-UBT. The breath samples at baseline and 30 min after taking the urea kit containing 75 mg 13 C-urea were assayed in the Taipei Institute of Pathology using an infrared spectrometer that produced computergenerated results. Positive result was defined as a delta value of 4 units as in our previous studies. 10, 25 All subjects were informed of the common side effects of the study drugs before eradication therapy and were asked to record these symptoms during treatment. We also arranged a standardized outpatient clinic interview at the end of treatment. The research staff assessed the adverse events and compliance using a pre-defined case report form and counted the pills not taken by the subjects. Compliance was defined as low when they took ,80% of the study drugs.
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Determination of phenotypic and genotypic resistance and CYP2C19 polymorphism
Agar dilution test was used to determine the MICs in the central laboratory in NTUH. 27 The resistance breakpoints for clarithromycin, amoxicillin, metronidazole, levofloxacin and tetracycline were defined as 1, 0.5, 8, .1 and .0.5 mg/L, respectively. 27 The 23S rRNA mutations were genotyped by PCR followed by direct sequencing using the automatic sequencer (ABI PRISM 3100 Genetic Analyzer; Applied Biosystems). 27 The VacA signal region (s1/2) and midregion (m1/2) mosaics were determined by the PCR method as described previously. 13, 16 The CYP2C19 polymorphism was genotyped by PCR followed by RFLP. 28 
Statistical analysis
We assumed the eradication rate of the optimized 14 day sequential therapy to be 94% and estimated a sample size of at least 310 in each group to detect a 7% difference in the eradication rate to give a statistical power of 80% at a 5% significance level on a two-sided test, assuming lost to followup rate of 10%. The sample size also allows adequate power to test the hypothesis that sequential therapy for 14 days is not inferior to bismuth quadruple therapy for 10 days by 5% to give a statistical power of 80% at a 5% significance level on a one-sided test. All randomized subjects were included in the ITT analysis of the eradication rate in the first-line therapy, the primary endpoint of this study. All protocol violators, such as patients with unknown H. pylori status after eradication therapy or those who took ,80% of study drugs, were excluded from the PP analysis. Patients with missing data on the safety issue were not included in the analysis. Categorical data were compared using the v 2 test or Fisher's exact test as appropriate. Continuous data were compared with Student's t-test and expressed as mean (SD). All P values were two-tailed, with the level of statistical significance specified as 0.05. The statistical analyses were performed using the SPSS statistical software (version 21) for Windows. The 95% CI of the eradication rate of each regimen was calculated.
Ancillary analysis
Multiple logistic regression analyses with the following predictors of interest: age, gender, gastric ulcer, duodenal ulcer, clarithromycin resistance (genotypic resistance using gastric biopsy specimen), compliance and CYP2C19 polymorphism were used to evaluate factors affecting the eradication rates. Patients with missing data were excluded in the regression analyses. We also constructed the Hp-normogram to predict the efficacies of the two regimens in regions with a different prevalence of clarithromycin resistance. 26 The data required for model generation were based on the eradication rates of ST14 and BQ10 according to the antibiotic resistance in the ITT and PP analysis, which were obtained from the present study. Assuming the eradication rate in strains susceptible and resistant to clarithromycin were A and B, respectively, the predicted eradication rate of that regimen would be A%(1 # p)!B % p, where the prevalence of clarithromycin was p (0p1). The predicted efficacies of ST14 and BQ10 according to the prevalence of clarithromycin resistance were plotted using Excel (Microsoft Office 2010; Microsoft Corporation, WA, USA).
Results
Baseline data and characteristics
From 23 September 2015 to 31 July 2017, a total of 620 patients were randomized (Figure 1 ). We performed biopsy for culture in 485 patients who underwent endoscopy due to upper gastrointestinal symptoms. Genotyping of 23S rRNA in gastric biopsy tissues was done in 471 patients. H. pylori was isolated in 394 patients and antibiotic susceptibility data were available in 383 patients.
Characteristics were similar across the two randomized groups (Table 1 ). There were no significant differences in the characteristics among patients recruited according to criterion 1 and 2 (Table  S1 , available as Supplementary data at JAC Online). The characteristics of patients with and without susceptibility tests were also similar (Table S2) . Detailed information is available in the Supplementary data.
H. pylori eradication rates
The eradication rates for ST14 and BQ10 were 91.3% (283 of 310, 95% CI 87.4%-94.1%) and 91.6% (284 of 310, 95% CI 87.8%-94.3%) in the ITT analysis, respectively, and were 93.9% (279 of 297, 95% CI 90.4%-96.3%) and 95.5% (277 of 290, 95% CI 92.3%-97.5%) in the PP analysis, respectively ( Table 2 ). ST14 was not inferior to BQ10 in the ITT analysis (difference #0.3%, 95% CI #4.7% to 4.4%, P " 0.886). In the second-line therapy, the eradication rate in BQ10 for patients who failed on ST14 was 80.0% (8 of 10, 95% CI 44.2%-96.5%, Table 2 ). The eradication rate of ST14 for patients who failed on BQ10 was 50.0% (5 of 10, 95% CI 20.1%-79.9%). Following two courses of antibiotic treatment, there was no significant difference in the overall eradication rates between the two algorithms of ST14/BQ10 and BQ10/ST14 in both the ITT and PP analyses ( Table 2) .
Adverse effects and compliance
The frequencies of any adverse effects in patients treated with ST14 and BQ10 were 36.7% (113 of 308, 95% CI 31.4%-42.4%) and 74.4% (230 of 309, 95% CI 69.1%-79.1%), respectively (P , 0.0001, Table 3 ). The frequencies of dizziness, nausea, vomiting, and darkened stool were significantly higher in patients treated with BQ10 than those treated with ST14 (Table 3 ). The compliance (taking at least 80% of the drugs) was similar in patients treated with ST14 and BQ10 ( Table 3 ). The frequency of adverse effects in the second-line treatment is shown in Table S3 .
Eradication rates according to antibiotic resistance, host CYP2C19 polymorphism and bacterial virulence factors
Clarithromycin resistance significantly affected the eradication rate of ST14, as shown in Table 4 (PP analysis). The results were consistent using different methods (genotypic and phenotypic) to detect clarithromycin resistance. The efficacy of BQ10 was not affected by clarithromycin or metronidazole resistance. The efficacies of ST14 and BQ10 were not significantly different in strains susceptible to both clarithromycin and metronidazole. However, the efficacy of BQ10 was higher than ST14 in the presence of clarithromycin resistance. The eradication rates of ST14 and BQ10 therapies were both significantly affected by compliance, but were not affected by the presence of gastric ulcer or duodenal ulcer, host CYP2C19 polymorphism, or bacterial virulence factors in the univariate analysis (Table 4 ). The ORs and 95% CI in the univariate analysis are shown in Table S4 . The eradication rates in subgroups in the first-line therapy according to ITT analysis are shown in Table S5 . A total of 226 and 227 patients with drug susceptibility data were included in the multiple logistic regression analyses in patients treated with ST14 and BQ10, respectively. Multiple Liou et al.
regression analyses showed that clarithromycin resistance significantly affected the efficacy of ST14, whereas poor compliance significantly affected the efficacy of BQ10 (Table 4) . Genotypic resistance (23S rRNA mutations) to clarithromycin using gastric biopsy tissues or H. pylori strains correlated well with phenotypic resistance detected by agar dilution test (Table S6) .
Hp-normogram
The predicted efficacies of ST14 and BQ10 according to the prevalence of clarithromycin resistance are shown in Figure S1 . The eradication rates of S14 and BQ10 in strains susceptible and resistant to clarithromycin as shown in Table 4 were used for the prediction. The eradication rate of both ST14 and BQ10 appeared to be .90% in regions with lower clarithromycin resistance ( Figure  S1 ). However, BQ10 appeared to be more effective than ST14 in regions with higher clarithromycin resistance.
Discussion
To the best of our knowledge, this is the first randomized trial to provide direct evidence that optimized 14 day sequential therapy was non-inferior to 10 day bismuth quadruple therapy and may be 14 day sequential vs 10 day quadruple therapy for H. pylori JAC used as an alternative therapy in populations with low and intermediate clarithromycin resistance. Both regimens were highly effective (.90%) in first-line therapy, but the frequency of adverse effects was significantly lower in patients treated with the optimized 14 day sequential therapy. Bismuth quadruple therapy is effective as recue therapy for patients who fail after optimized sequential therapy. However, 14 day sequential therapy is not effective as rescue therapy for patients who fail after bismuth quadruple therapy. The eradication rates of the optimized 14 day sequential therapy were 78.6% and 71.4% in the presence of single clarithromycin resistance and dual clarithromycin and metronidazole resistance, respectively, indicating that such an optimized regimen can partly overcome the clarithromycin resistance. The prediction model (Hp-normogram) derived from the results of this trial further suggest that the optimized 14 day sequential therapy may be an alternative first-line therapy in populations with low and intermediate clarithromycin resistance (,20%).
The results from this trial showed that efficacy of sequential therapy can be optimized through the addition of metronidazole, extending its treatment length to 14 days, and the use of a higher dosage of PPI. Meta-analysis of randomized trials showed that extending the treatment length of triple therapy to 14 days was superior to 7 or 10 day triple therapies. 15 Earlier trials and metaanalysis showed that 10 day sequential therapy was superior to 7 or 10 day triple therapy. 29, 30 However, subsequent trials and meta-analysis showed that 10 day sequential therapy was not superior to 14 day triple therapy. 12, 13, 16, 22 Besides, the eradication rate of 10 day sequential therapy was ,50% for patients infected with dual clarithromycin-and metronidazole-resistant strains. 12, 13, 16 Therefore, more recent consensus reports recommended against the use of sequential therapy (10 day). 9, 10 However, the situation is the same for concomitant therapy. Although several earlier trials showed that concomitant therapy given for 5, 7 or 10 days was superior to triple therapy given for 7 or 10 days, 31 a large randomized trial showed that 5 day concomitant therapy was inferior to 14 day triple therapy in Latin America. 22 Our recent randomized trial further showed that 10 day concomitant therapy was not superior to 14 day triple therapy in Taiwan. 17 A non-randomized trial showed that the optimized 14 day concomitant therapy was superior to 14 day triple therapy in Spain. 23 Therefore, the Toronto Consensus and the Maastricht V Consensus reports recommended the use of 14 day concomitant therapy as alternative first-line therapy. 9, 10 Our previous randomized trial in Taiwan and subsequent metaanalysis showed that 14 day sequential therapy was superior to 14 day triple therapy. 13, 14 The result from this trial further showed that the optimized 14 day sequential therapy containing highdose esomeprazole was non-inferior but better tolerated than 10 day bismuth quadruple therapy. The optimized 14 day sequential therapy contains only half the amount of antibiotics, is less costly than the optimized 14 day concomitant therapy and may be reconsidered as the first-line treatment for H. pylori infection. The eradication rate of 10 day bismuth quadruple therapy was already 95.5% in the PP analysis. Therefore, the benefit of extending the bismuth quadruple therapy to 14 days might be limited. However, whether reducing the frequency of tetracycline and metronidazole and extending its treatment length to 14 days may reduce the frequencies of adverse effects and increase the eradication rate in the ITT analysis deserves further investigation in future trials.
The relatively low eradication rate of sequential therapy for strains with dual resistance to clarithromycin and metronidazole is a concern. However, our study showed that the use of high-dose PPI may partly overcome this problem. In vitro studies have shown higher MICs for amoxicillin and clarithromycin in acidic environments. 32 Meta-analysis of randomized trials also showed that the use of a higher dose of PPI may increase the efficacy of standard triple therapy compared with a standard dose of PPI. 20 Recent studies further showed that optimized 14 day concomitant therapy containing high-dose esomeprazole was highly effective (.90%) and could overcome the dual clarithromycin and metronidazole resistance in Spain and Greece where the clarithromycin resistance rates were 18% and 40%, respectively. 23, 24, 33 Our results showed that the efficacy of the optimized 14 day sequential therapy was 78.6% in single clarithromycin-resistant strains and was 71.4% in dual clarithromycin-and metronidazole-resistant strains.
The strengths of this study included the large sample size, analysis of antibiotic resistance and assessment of the efficacy of optimized 14 day sequential therapy and bismuth quadruple therapy in the second-line rescue therapy. The result from this trial provides Liou et al.
evidence that optimized 14 day sequential therapy is not inferior to bismuth quadruple therapy. Both regimens were highly effective (grade A regimens according to the report card of H. pylori eradication) 34 in regions with clarithromycin resistance of 15%. The determination of antibiotic resistance allowed us to predict the efficacy of the two regimens in regions with different prevalences of clarithromycin resistance. However, the inference from the Hpnormogram suggests that bismuth quadruple therapy would be more effective than the optimized 14 day sequential therapy in regions with high clarithromycin resistance. Although a previous trial has shown that 10 day sequential therapy was not superior to 10 day bismuth quadruple therapy in Hong Kong, 35 we further demonstrated that 14 day sequential therapy was non-inferior to 10 day bismuth quadruple therapy. Besides, antibiotic resistance was not determined in that trial. 35 There are some limitations of this study. First, the complexity of sequential therapy and bismuth quadruple therapy might limit their widespread application in first-line treatment. However, a single capsule containing bismuth, tetracycline and metronidazole is available that can simplify the drug administration of bismuth quadruple therapy. Besides, several types of inexpensive and convenient pill dispenser have been developed to simplify the drug administration of variable dosage and frequency. Second, the use of two recruitment criteria might introduce selection bias. However, the characteristics among patients recruited using different criteria were not significantly different owing to adequate randomization (Table S1 ). Third, the MIC was not available in 38% of study participants because culture was not done in 135 patients (21.7%) and the culture rate (81.2%, 394 of 485) was less than perfect. However, the demographic characteristics and the eradication rates were also similar among those with and without the MIC test in the two treatment groups, indicating that the confounding effect has been minimized through randomization (Table S2) . Finally, the optimized 14 day sequential therapy is not recommended in regions with high clarithromycin resistance. Bismuth quadruple therapy, levofloxacin-containing sequential therapy or levofloxacin-containing concomitant therapy would be more effective and are the treatments of choice in such circumstances. 21, 36, 37 
Conclusions
The optimized 14 day sequential therapy was not inferior to and was better tolerated than 10 day bismuth quadruple therapy in Liou et al.
